The concept of a ‘global public good’ is an economic idea that at its simplest, refers to products, ideas, policies or issues with effects that could extend to everyone, everywhere. Despite its name, this actually has nothing to do with good or bad effects, as the word “good” here refers to products, rather than something that is beneficial or positive. In the context of health, this usually means programmes, policies and services that have a truly global impact on health, usually positive impacts, even though those benefits or costs may not be equitable across the world.

So slightly confusingly perhaps, a global public good can involve something that is good or bad – it is something that can have benefits or costs that reach the entire world. Global warming is a useful example of an issue that is a global public good that has disastrously negative effects for the entire world.

Global public goods must be non-rivalrous – meaning that using it doesn’t reduce the amount for anyone else, although activities or interventions concerning it may well be. They must also be non-excludable, meaning that it should be impossible to prevent anyone else from getting the benefits. Films are an example of a good that is non-rivalrous – one person enjoying a film doesn’t affect how someone else enjoys it – but it can be excludable from someone who doesn’t pay to access the film.

Global public goods must be non-rivalrous – meaning that using it doesn’t reduce the amount for anyone else, although activities or interventions concerning it may well be.

Global public goods in healthcare

Organisations such as the World Health Organization (WHO) provide a range of global public goods, in the form of open access publications, standards (e.g. the International Classification of Disease), guidelines (e.g. for HIV treatment in resource-poor settings), assessments (e.g. pre-qualification of drugs and vaccines), coordinating frameworks (e.g. Global Action Plan on Antimicrobial Resistance), voluntary normative guidance (e.g. Code of Conduct on Marketing of Breastmilk Substitute) or binding international law (e.g. the International Health Regulations and the Framework Convention on Tobacco Control).

Disease eradication meets the criteria of both being non-rivalrous and non-excludable. The eradication of a vaccine-preventable disease, such as smallpox, qualifies since everyone benefits, whether or not they contributed to the eradication effort.


Read more: Gavi's Vaccine support


Who governs and finances global public goods?

Clearly, unlike non-health-related global public goods, such as sunlight, which exists without human intervention, the provision of some health-related ones need sustained planning and financing. Their provision is not automatically assured.

Financing brings issues both of coordination and of governance – who is in charge of a global public good, who decides the priorities, and who decides where the money goes?

In some instances, where sovereign interests can’t be coordinated easily for a global goal that is much needed, international agencies have taken the reins, often along with philanthropic funding. Gavi’s mission is a good example of this, in which a core group of partners decided to innovate ways to ensure that childhood vaccination would be available to anyone who needs it. It is also a prime example of a public-private partnership taking a private good (a vaccine) and making it public.

To ensure sustainable financing, some global health academics like Suerie Moon at Harvard, and others, have suggested a Global Fund for Public Goods (GFPG), in to which all countries would contribute to fund, for instance, R&D with a global reach. Ensuring all countries contribute to such a fund can be challenging because global public goods can be undermined by “free riders”, who essentially want to reap the benefits without contributing as much as might be needed – free-riding off the goodwill and contributions of others.


Read more: Gavi's Innovative financing


Vaccines as a global public good

While disease eradication as a whole is a global public good, it becomes more complex when you look specifically at health products. Drugs and vaccines are often both rivalrous and excludable – for example, if prices are set so high that low- and middle-income countries can’t afford to buy them, or if there are supply issues.

However, as Moon and colleagues point out: “excludability is not immutable”, and societal and political decisions can influence whether or not a good is made non-excludable. Researchers, for example, could publish their work in a journal that has a paywall or one that has open-access, and similarly, scientists could decide to patent a technology or make it free to use, depending on the circumstances. 

This ability to make private goods or products public, when the right to health demands it, was reflected in the lead up to this year’s World Health Assembly (WHA). Countries debated whether there should be a reference to global public goods in a UN resolution, the “International cooperation to ensure global access to medicines, vaccines and medical equipment to face COVID-19”. UNAIDS called for a “People’s vaccine” against COVID-19 that would be available to everyone, in all countries, free of charge. The UN General Assembly resolution ended up including global public goods as a concept in this way: “the role of extensive immunisation against COVID-19 as a global public good for health in preventing, containing and stopping transmission in order to bring the pandemic to an end, once safe, quality, efficacious, effective, accessible and affordable vaccines are available…”


Read more: COVAX


To enact this resolution and ensure mandatory worldwide sharing of all COVID-19-related knowledge, data and technologies, countries will most likely need to make full use of agreed safeguards and flexibilities in the World Trade Organization Doha Declaration on the TRIPS and Public Health, to protect access to medicines for all. These are agreements that allow countries to lift patents on medicines if it is in the public interest, as Brazil did with antiretrovirals in 2007, although this was not an easy process for the country and brought a significant backlash from pharmaceutical companies.

When it comes to vaccines, the call to make them affordable and available to everyone, everywhere – essentially, to make vaccines a global public good – is embedded in the idea of universal health coverage. In a world living with concurrent severe epidemics of cholera and measles, and now dealing with the COVID-19 pandemic, the need for affordable and available vaccines is more urgent than ever. 

Related content

21 September 2020

Rwanda: Changing perceptions

18 September 2020

Why vaccines?

15 September 2020

Malawi: Reaching girls earlier

9 September 2020

The COVID-19 vaccine race

3 September 2020

COVAX explained

28 August 2020

Q&A with Helen Rees

14 April 2020

COVID-19 News in Brief

26 March 2020

What is herd immunity?

19 March 2020

COVID-19: Q&A

8 March 2020

ScienceSHEroes

15 October 2018

Good data saves lives

18 September 2018

Blue skies thinking

5 September 2018

Preventing cholera in Zambia

1 June 2018

Girl Effect and Gavi

4 December 2017

@Vaccines to #TakeOnTyphoid

7 November 2017

@Vaccines to Stop Pneumonia

23 October 2017

@Vaccines work to #EndPolio

28 February 2017

@Vaccines for a Shot At Life

18 September 2016

@Vaccines at UNGA

29 April 2016

Immunization under fire

10 March 2016

@Vaccines for South Asia

29 February 2016

@Vaccines for a Shot at Life

28 February 2016

vaccineworks – no title

14 February 2016

vaccineworks – no title

7 February 2016

vaccineworks – no title

14 January 2016

Les dix ans du REPAOC

30 December 2015

vaccineworks – no title

8 December 2015

Polio: the last mile

8 December 2015

vaccineworks – no title

6 December 2015

vaccineworks – no title

29 November 2015

vaccineworks – no title

25 November 2015

vaccineworks – no title

22 November 2015

vaccineworks – no title

18 November 2015

The Art of @Vaccines

16 November 2015

I am the donation

9 November 2015

A foundation for @Vaccines

24 October 2015

vaccineworks – no title

19 October 2015

@Vaccines against polio

22 September 2015

Cartoon: how do vaccines work?

14 August 2015

vaccineworks – no title

22 June 2015

Dr Clarisse @Vaccines

8 June 2015

@Vaccines ACTION

28 May 2015

ONE @Vaccines

24 February 2015

vaccineworks – no title

18 February 2015

vaccineworks – no title

18 February 2015

vaccineworks – no title

11 February 2015

vaccineworks – no title

6 February 2015

Faith in Vaccines

6 February 2015

vaccineworks – no title

26 January 2015

vaccineworks – no title

25 January 2015

vaccineworks – no title

23 January 2015

vaccineworks – no title

21 January 2015

vaccineworks – no title

18 December 2014

vaccineworks – no title

11 December 2014

5 almost vaccines

1 December 2014

vaccineworks – no title

24 November 2014

vaccineworks – no title

30 October 2014

From Tweet to Shot

27 October 2014

vaccineworks – no title

24 August 2014

vaccineworks – no title

22 August 2014

vaccineworks – no title

11 August 2014

vaccineworks – no title

11 August 2014

vaccineworks – no title

Subscribe to our newsletter